{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:55:21Z","timestamp":1780113321265,"version":"3.54.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Department of Biotechnology, Government of India","award":["BT\/PR18008\/NNT\/28\/1055\/2016"],"award-info":[{"award-number":["BT\/PR18008\/NNT\/28\/1055\/2016"]}]},{"name":"Department of Biotechnology, Government of India","award":["BT\/PR18008\/NNT\/28\/1055\/2016"],"award-info":[{"award-number":["BT\/PR18008\/NNT\/28\/1055\/2016"]}]},{"name":"Department of Biotechnology, Government of India","award":["BT\/PR18008\/NNT\/28\/1055\/2016"],"award-info":[{"award-number":["BT\/PR18008\/NNT\/28\/1055\/2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13346-020-00764-x","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:02:19Z","timestamp":1588896139000},"page":"945-961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nanotechnological interventions for treatment of trypanosomiasis in humans and animals"],"prefix":"10.1007","volume":"10","author":[{"given":"Kedar","family":"Prayag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanashree H.","family":"Surve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish T.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil B.","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"764_CR1","unstructured":"WHO Report on trypansomiasis 2013. Control and surveillance of human African trypanosomiasis 2001."},{"key":"764_CR2","unstructured":"WHO Trypansomiasis. WHO-Trypansomiasis, International travel & health issue [Internet]. [cited 2019 Jul 10]. Available from: https:\/\/www.who.int\/ith\/diseases\/trypanosomiasis\/en\/"},{"key":"764_CR3","unstructured":"WHO. WHO_Trypanosomiasis_Countries at risk [Internet]. [cited 2019 Jul 11]. Available from: https:\/\/www.who.int\/trypanosomiasis_african\/country\/risk_AFRO\/en\/"},{"key":"764_CR4","unstructured":"WHO- Chagas Disease. WHO_Chagas disease_Epidemology [Internet]. [cited 2019 Jul 11]. Available from: https:\/\/www.who.int\/chagas\/epidemiology\/en\/"},{"key":"764_CR5","first-page":"319","volume":"49","author":"KML Pathak","year":"1993","unstructured":"Pathak KML, Arora JK, Kapoor M. Short communication camel trypanosomosis in Rajasthan. India Vertirnary Parasitol. 1993;49:319\u201323.","journal-title":"India Vertirnary Parasitol"},{"key":"764_CR6","unstructured":"Chandrasekar PH. African trypanosomiasis. Medscape Rev. 2018. p. 1\u201314."},{"key":"764_CR7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","volume":"107","author":"P Babokhov","year":"2013","unstructured":"Babokhov P, Sanyaolu AO, Oyibo WA, Fagbenro-beyioku AF, Iriemenam NC. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health. 2013;107:242\u201352.","journal-title":"Pathog Glob Health"},{"key":"764_CR8","first-page":"1155","volume":"2007","author":"MP Barrett","year":"2005","unstructured":"Barrett MP, Boykin DW, Brun R, Tidwell RR. Review: Frontiers in Pharmacology. Human African trypanosomiasis : pharmacological re-engagement with a neglected disease. Br J Pharmacol. 2005;2007:1155\u201371.","journal-title":"Br J Pharmacol"},{"key":"764_CR9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/oxfordjournals.bmb.a072044","volume":"41","author":"WE Gutteridge","year":"1985","unstructured":"Gutteridge WE. Existing chemotherapy and its limitations. Br Med Bull. 1985;41:162\u20138.","journal-title":"Br Med Bull"},{"key":"764_CR10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pt.2003.09.002","volume":"19","author":"AH Fairlamb","year":"2003","unstructured":"Fairlamb AH. Chemotherapy of human African trypanosomiasis : current and future prospects. Trends Parasitol. 2003;19:488\u201394.","journal-title":"Trends Parasitol"},{"key":"764_CR11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pt.2012.12.005","volume":"29","author":"N Baker","year":"2013","unstructured":"Baker N, De Koning HP, Ma P, Horn D. Drug resistance in African trypanosomiasis : the melarsoprol and pentamidine story. Trends Parasitol. 2013;29:110\u20138.","journal-title":"Trends Parasitol"},{"key":"764_CR12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","volume":"375","author":"R Brun","year":"2010","unstructured":"Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375:148\u201359.","journal-title":"Lancet."},{"key":"764_CR13","doi-asserted-by":"crossref","unstructured":"Giordani F, Morrison LJ, Rowan TIMG, Koning HPDE, Barrett MP. The animal trypanosomiases and their chemotherapy : a review. Parasitology. 2017:1862\u201389.","DOI":"10.1017\/S0031182016001268"},{"key":"764_CR14","first-page":"727","volume":"4","author":"R Pink","year":"2005","unstructured":"Pink R, Hudson A, Mouri\u00e8s M, Bendig M. Opprtunities and challenges in anti-parasitic drug discovery. Natl Rev. 2005;4:727\u201340.","journal-title":"Natl Rev"},{"key":"764_CR15","doi-asserted-by":"crossref","unstructured":"Thomas JA, Baker N, Hutchinson S, Id CD, Trenaman A, Id LG, et al. Insights into antitrypanosomal drug mode-of- action from cytology-based profiling. PLoS Negl Trop Dis. 2018:1\u201319.","DOI":"10.1371\/journal.pntd.0006980"},{"key":"764_CR16","first-page":"1","volume":"4","author":"O Yun","year":"2010","unstructured":"Yun O, Priotto G, Tong J, Flevaud L. NECT is next : implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010;4:1\u20135.","journal-title":"PLoS Negl Trop Dis"},{"key":"764_CR17","first-page":"93","volume":"3","author":"M Samo","year":"2012","unstructured":"Samo M, Jannin JG. Monitoring the use of nifurtimox-eflornithine combination therapy ( NECT ) in the treatment of second stage gambiense human African trypanosomiasis. Res Rep Trop Med. 2012;3:93\u2013101.","journal-title":"Res Rep Trop Med"},{"key":"764_CR18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2885.1988.tb00148.x","volume":"11","author":"B Road","year":"1988","unstructured":"Road B. The pharmacology of isometamidium. J vet Pharmacol Therp. 1988;11:233\u201345.","journal-title":"J vet Pharmacol Therp"},{"key":"764_CR19","doi-asserted-by":"crossref","unstructured":"Desquesnes M, Dargantes A, Lai D, Lun Z, Holzmuller P, Jittapalapong S. Trypanosoma evansi and Surra : a review and perspectives on transmission, epidemiology and control, impact, and zoonotic aspects. Biomed Res Int 2013;1\u201320.","DOI":"10.1155\/2013\/321237"},{"key":"764_CR20","unstructured":"Biobaku BY. Antiprotozoan drugs at a glance [Internet]. Available from: http:\/\/unaab.edu.ng\/wp-content\/uploads\/2009\/12\/484_ANTIPROTPOZOAN AGENTS.pdf."},{"key":"764_CR21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/00001432-200012000-00012","volume":"13","author":"MP Barrett","year":"2000","unstructured":"Barrett MP. Problems for the chemotherapy of human African trypanosomiasis. Curr Opin Infect Dis. 2000;13:647\u201351.","journal-title":"Curr Opin Infect Dis"},{"key":"764_CR22","unstructured":"WHO. Chagas disease (American trypanosomiasis)."},{"key":"764_CR23","unstructured":"Health T center for food security and public. American Trypanosomiasis (Chagas Disease ). 2017."},{"key":"764_CR24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.addr.2009.11.025","volume":"62","author":"EL Romero","year":"2010","unstructured":"Romero EL, Morilla MJ. Nanotechnological approaches against Chagas disease. Adv Drug Deliv Rev. 2010;62:576\u201388.","journal-title":"Adv Drug Deliv Rev"},{"key":"764_CR25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.pt.2003.09.001","volume":"19","author":"JA Urbina","year":"2005","unstructured":"Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2005;19:495\u2013501.","journal-title":"Trends Parasitol"},{"key":"764_CR26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/17425247.2011.574122","volume":"8","author":"M Kroubi","year":"2011","unstructured":"Kroubi M, Karembe H, Betbeder D. Drug delivery systems in the treatment of African trypanosomiasis infections. Expert Opin Drug Deliv. 2011;8:735\u201347.","journal-title":"Expert Opin Drug Deliv"},{"key":"764_CR27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actatropica.2017.02.019","volume":"170","author":"GA Islan","year":"2017","unstructured":"Islan GA, Dur\u00e1n M, Cacicedo ML, Nakazato G, Kobayashi RKT, Martinez DST, et al. Nanopharmaceuticals as a solution to neglected diseases : is it possible ? Acta Trop. 2017;170:16\u201342.","journal-title":"Acta Trop"},{"key":"764_CR28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/nnm.14.185","volume":"10","author":"EL Romero","year":"2015","unstructured":"Romero EL. Nanomedicines against Chagas disease : an update on therapeutics , prophylaxis and diagnosis. Nanomedicine. 2015;10:465\u201381.","journal-title":"Nanomedicine."},{"key":"764_CR29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","volume":"59","author":"AA Date","year":"2007","unstructured":"Date AA, Joshi MD, Patravale VB. Parasitic diseases : liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev. 2007;59:505\u201321.","journal-title":"Adv Drug Deliv Rev"},{"key":"764_CR30","first-page":"1","volume":"8","author":"KCF Lidani","year":"2017","unstructured":"Lidani KCF, Bavia L, Ambrosio AR, De Messias-reason IJ, Barbosa AS. The complement system : a prey of Trypanosoma cruzi. Front Microbiol. 2017;8:1\u201314.","journal-title":"Front Microbiol"},{"key":"764_CR31","doi-asserted-by":"crossref","unstructured":"Simarro PP. Epidemiology of human African trypanosomiasis. Clin epidemology. 2014:257\u201375.","DOI":"10.2147\/CLEP.S39728"},{"key":"764_CR32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1242\/jcs.01649","volume":"118","author":"KR Matthews","year":"2005","unstructured":"Matthews KR. The developmental cell biology of Trypanosoma brucei. J Cell Sci. 2005;118:283\u201390.","journal-title":"J Cell Sci"},{"key":"764_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.10342.2","volume":"6","author":"TK Smith","year":"2017","unstructured":"Smith TK, Bringaud F, Nolan DP, Figueiredo LM. Metabolic reprogramming during the Trypanosoma brucei life cycle. F1000 Res. 2017;6:1\u201312.","journal-title":"F1000 Res"},{"key":"764_CR34","unstructured":"Centers for Disease control and Prevention [Internet]. African Trypanos. [cited 2020 Jan 18]. Available from: https:\/\/www.cdc.gov\/parasites\/sleepingsickness\/index.html"},{"key":"764_CR35","first-page":"1","volume":"3","author":"E Rico","year":"2013","unstructured":"Rico E, Rojas F, Mony BM, Szoor B, Macgregor P. Bloodstream form pre-adaptation to the tsetse fly in Trypanosoma brucei. Cell Infect Microbiol. 2013;3:1\u201315.","journal-title":"Cell Infect Microbiol"},{"key":"764_CR36","doi-asserted-by":"crossref","unstructured":"Garcia-salcedo JA, Munday JC, Unciti-broceta JD, De Koning HP Progress towards new treatments for human African trypanosomiasis. Trypanos Trypanos. 2014. p. 217\u201338.","DOI":"10.1007\/978-3-7091-1556-5_9"},{"key":"764_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-00959-w","volume":"8","author":"J Pinger","year":"2017","unstructured":"Pinger J, Chowdhury S, Papavasiliou FN. Variant surface glycoprotein density defines an trypanosomes undergoing antigenic variation. Nat Commun. 2017;8:1\u20139.","journal-title":"Nat Commun"},{"key":"764_CR38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1590\/S1807-59322009001200013","volume":"64","author":"NM Matsuda","year":"2009","unstructured":"Matsuda NM, Miller ISM, Paulo II, Evora RB. The chronic gastrointestinal manifestations of Chagas disease. Clinics. 2009;64:1219\u201324.","journal-title":"Clinics."},{"key":"764_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006939","volume":"12","author":"\u00cd Rodrigues-dos-Santos","year":"2018","unstructured":"Rodrigues-dos-Santos \u00cd, Melo MF, de Castro L, Hasslocher-Moreno AM, do Brasil PEAA, de Silvestre Sousa A, et al. Exploring the parasite load and molecular diversity of Trypanosoma cruzi in patients with chronic Chagas disease from different regions of Brazil. PLoS Negl Trop Dis. 2018;12:1\u201319.","journal-title":"PLoS Negl Trop Dis"},{"key":"764_CR40","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/CMR.00063-10","volume":"24","author":"ARL Teixeira","year":"2011","unstructured":"Teixeira ARL, Hecht MM, Guimaro MC, Sousa AO, Nitz N. Pathogenesis of chagas\u2019 disease: parasite persistence and autoimmunity. Clin Microbiol Rev. 2011;24:592\u2013630.","journal-title":"Clin Microbiol Rev"},{"key":"764_CR41","unstructured":"Chagas Disease [Internet]. Centers Dis. Control Prev. [cited 2020 Jan 18]. Available from: https:\/\/www.cdc.gov\/parasites\/chagas\/index.html"},{"key":"764_CR42","unstructured":"Nenarokova A, Michels PAM. A paradigm shift : the mitoproteomes of procyclic and bloodstream Trypanosoma brucei are comparably complex. PLoS Pathog. 2017:1\u20139."},{"key":"764_CR43","first-page":"1872","volume":"264","author":"P Borst","year":"2016","unstructured":"Borst P, Rudenko G, Borst P. Antigenic variation in African trypanosomes published by: American Association for the Advancement of Science Antigenic Variation in African Trypanosomes. Am Assoc Adv Sci. 2016;264:1872\u20133.","journal-title":"Am Assoc Adv Sci"},{"key":"764_CR44","doi-asserted-by":"crossref","unstructured":"Mugnier MR, Stebbins CE, Papavasiliou FN. Masters of disguise : antigenic variation and the VSG coat in Trypanosoma brucei. PLoS Pathog. 2016:1\u20136.","DOI":"10.1371\/journal.ppat.1005784"},{"key":"764_CR45","doi-asserted-by":"crossref","unstructured":"Bangs JD. Evolution of antigenic variation in African trypanosomes: variant surface glycoprotein expression, structure, and function. BioEssays. 2018;1800181:1\u20138.","DOI":"10.1002\/bies.201800181"},{"key":"764_CR46","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1017\/S0031182012000169","volume":"139","author":"PP Simarro","year":"2012","unstructured":"Simarro PP, Franco J, Diarra A, Postigo JAR, Jannin J. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology. 2012;139:842\u20136.","journal-title":"Parasitology."},{"key":"764_CR47","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jconrel.2004.02.024","volume":"96","author":"C Olbrich","year":"2004","unstructured":"Olbrich C, Gessner A, Schro W, Kayser O, Mu RH. Lipid \u2013 drug conjugate nanoparticles of the hydrophilic drug diminazene \u2014 cytotoxicity testing and mouse serum adsorption. J Control Release. 2004;96:425\u201335.","journal-title":"J Control Release"},{"key":"764_CR48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/14728214.7.1.61","volume":"7","author":"P Olliaro","year":"2002","unstructured":"Olliaro P, Lazdins J, Guhl F. Developments in the treatment of leishmaniasis and trypanosomiasis. Expert Opin Emerg Drugs. 2002;7:61\u20137.","journal-title":"Expert Opin Emerg Drugs"},{"key":"764_CR49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.vetpar.2014.04.002","volume":"203","author":"A Sahin","year":"2014","unstructured":"Sahin A, Asencio C, Izotte J, Pillay D, Coustou V, Karembe H, et al. Veterinary Parasitology The susceptibility of Trypanosoma congolense and Trypanosoma brucei to isometamidium chloride and its synthetic impurities. Vet Parasitol. 2014;203:270\u20135.","journal-title":"Vet Parasitol"},{"key":"764_CR50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpba.2007.08.026","volume":"46","author":"GJ Schad","year":"2008","unstructured":"Schad GJ, Allanson A, Mackay SP, Cannavan A, Tettey JNA. Development and validation of an improved HPLC method for the control of potentially counterfeit isometamidium products. J Pharm Biomed Anal. 2008;46:45\u201351.","journal-title":"J Pharm Biomed Anal"},{"key":"764_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/iti0112109","volume":"109","author":"N Baker","year":"2012","unstructured":"Baker N, Glover L, Munday JC, Aguinaga D, Barrett MP, De Koning HP, et al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. PNAS. 2012;109:1\u20136.","journal-title":"PNAS."},{"key":"764_CR52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pt.2005.08.026","volume":"21","author":"SL Croft","year":"2005","unstructured":"Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 2005;21:508\u201312.","journal-title":"Trends Parasitol"},{"key":"764_CR53","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","volume":"55","author":"M Kaiser","year":"2011","unstructured":"Kaiser M, Bray MA, Cal M, Trunz BB, Torreele E, Brun R. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011;55:5602\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR54","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/QCO.0b013e32833f9fd0","volume":"23","author":"MP Barrett","year":"2010","unstructured":"Barrett MP. Potential new drugs for human African trypanosomiasis : some progress at last Michael P. Curr Opin Infect Dis. 2010;23:603\u2013308.","journal-title":"Curr Opin Infect Dis"},{"key":"764_CR55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1574-695X.2009.00615.x","volume":"58","author":"A Cavalli","year":"2010","unstructured":"Cavalli A, Lizzi F, Bongarzone S, Belluti F, Piazzi L, Maria C, et al. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. Immunol Med Microbiol. 2010;58:51\u201360.","journal-title":"Immunol Med Microbiol"},{"key":"764_CR56","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/522982","volume":"45","author":"G Priotto","year":"2007","unstructured":"Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, et al. Nifurtimox-eflornithine combination therapy for second- stage Trypanosoma brucei gambiense sleeping sickness : a randomized clinical trial in Congo. Clin Infect Dis. 2007;45:1435\u201342.","journal-title":"Clin Infect Dis"},{"key":"764_CR57","doi-asserted-by":"crossref","unstructured":"Aksoy S, Buscher P, Lehane M, Solano P, Van Den Abbeele J. Human African trypanosomiasis control : achievements and challenges. PLoS Negl Trop Dis. 2017:1\u20136.","DOI":"10.1371\/journal.pntd.0005454"},{"key":"764_CR58","volume-title":"Application to include Nifurtimox-Eflornithine combination as treatment for stage 2 trypanosoma brucei gambiense human African trypanosomiasis","author":"OV Mordt","year":"2013","unstructured":"Mordt OV. Application to include Nifurtimox-Eflornithine combination as treatment for stage 2 trypanosoma brucei gambiense human African trypanosomiasis. Geneva: Switzerland; 2013. p. 1\u201398"},{"key":"764_CR59","first-page":"1","volume":"4","author":"MA Bray","year":"2010","unstructured":"Bray MA, Pe B. Fexinidazole \u2013 a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4:1\u201315.","journal-title":"PLoS Negl Trop Dis"},{"key":"764_CR60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.pt.2018.08.006","volume":"34","author":"CH Baker","year":"2018","unstructured":"Baker CH, Welburn SC. The long wait for a new drug for human African trypanosomiasis. Trends Parasitol. 2018;34:818\u201327.","journal-title":"Trends Parasitol"},{"key":"764_CR61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jeu.12184","volume":"62","author":"JA Urbina","year":"2015","unstructured":"Urbina JA. Recent clinical trials for the etiological treatment of chronic Chagas disease : advances , Challenges and Perspectives. J Eukaryot Microbiol. 2015;62:149\u201356.","journal-title":"J Eukaryot Microbiol"},{"key":"764_CR62","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/AAC.44.9.2498-2502.2000","volume":"44","author":"JA Urbina","year":"2000","unstructured":"Urbina JA, Lira R, Visbal G, De Qu\u0131 L. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma ( Schizotrypanum ) cruzi. Antimicrob Agents Chemother. 2000;44:2498\u2013502.","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR63","doi-asserted-by":"crossref","unstructured":"Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase *. 2001;276:33930\u20137.","DOI":"10.1074\/jbc.M103950200"},{"key":"764_CR64","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/AAC.22.4.657","volume":"22","author":"RL Berens","year":"1982","unstructured":"Berens RL, Marr JJ, Steele F, Cruz DA, Donald J. Effect of allopurinol on Trypanosoma cruzi : metabolism and biological activity in intracellular and bloodstream forms. Antimicrob Agents Chemother. 1982;22:657\u201361.","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR65","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1128\/AAC.46.11.3472-3477.2002","volume":"46","author":"VB Saraiva","year":"2002","unstructured":"Saraiva VB, Gibaldi D, Previato O, Mendonc L, Bozza MT, Freire-de-lima G, et al. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (Miltefosine ) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother. 2002;46:3472\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"764_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1004114","volume":"10","author":"N Shang","year":"2014","unstructured":"Shang N, Li Q, Ko T, Chan H, Li J, Zheng Y, et al. Squalene synthase as a target for Chagas disease therapeutics. PLoS Pathog. 2014;10:1\u201316.","journal-title":"PLoS Pathog"},{"key":"764_CR67","doi-asserted-by":"crossref","unstructured":"Salas-sarduy E, Ur\u00e1n L, Karpiak JX, Madauss KP, Jos\u00e9 J. Novel scaffolds for inhibition of Cruzipain identified from high- throughput screening of anti- kinetoplastid chemical boxes. Nature-Scientific Reports. 2017:1\u201312.","DOI":"10.1038\/s41598-017-12170-4"},{"key":"764_CR68","doi-asserted-by":"crossref","first-page":"17075","DOI":"10.1074\/jbc.M210467200","volume":"278","author":"A Montalvetti","year":"2003","unstructured":"Montalvetti A, Fernandez A, Sanders M, Ghosh S, Van E, Oldfield E, et al. Metaboolism and bioenergetics : farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei : in-vitro RNA interference and in-vivo inhibition studies farnesyl pyrophosphate synthase. J Biol Chem. 2003;278:17075\u201383.","journal-title":"J Biol Chem"},{"key":"764_CR69","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2174\/092986710791556023","volume":"17","author":"M Berg","year":"2010","unstructured":"Berg M, Van Der Veken P, Goeminne A, Haemers A, Augustyns K. Inhibitors of the purine salvage pathway : a valuable approach for antiprotozoal chemotherapy ? Curr Med Chem. 2010;17:2456\u201381.","journal-title":"Curr Med Chem"},{"key":"764_CR70","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nature08893","volume":"464","author":"JA Frearson","year":"2010","unstructured":"Frearson JA, Brand S, Mcelroy SP, Cleghorn LAT, Smid O, Stojanovski L, et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature. 2010;464:728\u201332.","journal-title":"Nature."},{"key":"764_CR71","doi-asserted-by":"crossref","unstructured":"Zhang RX, Li J, Zhang T, Amini MA, He C, Lu B, et al. Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy \u2013 an illustration with firsthand examples. Acta Pharmacol Sin Nature Publishing Group; 2018;1\u201320.","DOI":"10.1038\/aps.2018.33"},{"key":"764_CR72","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1016\/j.biomaterials.2010.01.065","volume":"31","author":"C He","year":"2010","unstructured":"He C, Hu Y, Yin L, Tang C, Yin C. Biomaterials effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31:3657\u201366.","journal-title":"Biomaterials."},{"key":"764_CR73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10611860400013451","volume":"12","author":"G Kaul","year":"2004","unstructured":"Kaul G, Amiji M. Biodistribution and targeting potential of poly ( ethylene glycol ) -modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target. 2004;12:585\u201391.","journal-title":"J Drug Target"},{"key":"764_CR74","doi-asserted-by":"crossref","unstructured":"Press D. Nanotechnology-based approaches in anticancer research. Int J Nanomedicine. 2012:4391\u2013408.","DOI":"10.2147\/IJN.S33838"},{"key":"764_CR75","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.2147\/IJN.S165451","volume":"13","author":"Y Luo","year":"2018","unstructured":"Luo Y. Effects of core size and PEG coating layer of iron oxide nanoparticles on the distribution and metabolism in mice. Int J Nanomedicine. 2018;13:5719\u201331.","journal-title":"Int J Nanomedicine"},{"key":"764_CR76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13346-016-0304-0","volume":"6","author":"AB Jindal","year":"2016","unstructured":"Jindal AB. Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential. Drug Deliv Transl Res. 2016;6:473\u201385.","journal-title":"Drug Deliv Transl Res"},{"key":"764_CR77","doi-asserted-by":"crossref","unstructured":"Cole AJ, David AE, Wang J, Galb\u00e1n CJ, Yang VC. Biomaterials magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials. 2011;32:6291\u20136301, Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles.","DOI":"10.1016\/j.biomaterials.2011.05.024"},{"key":"764_CR78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, En LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351.","journal-title":"Adv Drug Deliv Rev"},{"key":"764_CR79","doi-asserted-by":"crossref","unstructured":"Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu. A focus on nanoparticles as a drug delivery system. Nanomedicine. 2012;7:1253\u20131271.","DOI":"10.2217\/nnm.12.87"},{"key":"764_CR80","unstructured":"Maniruzzaman M, Douroumis D, Boateng AD. Recent advances in Novel drug carrier systems. Intech Open; 2012."},{"key":"764_CR81","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.addr.2012.11.006","volume":"65","author":"F Yamashita","year":"2013","unstructured":"Yamashita F, Hashida M. Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev. 2013;65:139\u201347.","journal-title":"Adv Drug Deliv Rev"},{"key":"764_CR82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2012.05.052","volume":"164","author":"S Muro","year":"2012","unstructured":"Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release. 2012;164:125\u201337.","journal-title":"J Control Release"},{"key":"764_CR83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1383-5769(99)00018-5","volume":"48","author":"D Steverding","year":"2000","unstructured":"Steverding D. The transferrin receptor of Trypanosoma brucei. Parasitol Int. 2000;48:191\u20138.","journal-title":"Parasitol Int"},{"key":"764_CR84","doi-asserted-by":"crossref","unstructured":"Molina-portela MP, Samanovic M, Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. 2008","DOI":"10.1084\/jem.20071463"},{"key":"764_CR85","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","volume":"59","author":"LM Bareford","year":"2007","unstructured":"Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59:748\u201358.","journal-title":"Adv Drug Deliv Rev"},{"key":"764_CR86","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3762\/bjnano.9.98","volume":"9","author":"J Jeevanandam","year":"2018","unstructured":"Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials : history , sources , toxicity and regulations. Beilstein J Nanotechnol. 2018;9:1050\u201374.","journal-title":"Beilstein J Nanotechnol"},{"key":"764_CR87","doi-asserted-by":"crossref","unstructured":"Unciti-broceta JD, Arias JL, Maceira J, Soriano M. Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis. PLoS Pathog. 2015:1\u201320.","DOI":"10.1371\/journal.ppat.1004942"},{"key":"764_CR88","doi-asserted-by":"crossref","unstructured":"Conrath K, Vanhollebeke B, Pays E, Baral TN, Magez S, Muyldermans S, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor 2006;12:580\u20134.","DOI":"10.1038\/nm1395"},{"key":"764_CR89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2009.04.035","volume":"379","author":"J Chang","year":"2009","unstructured":"Chang J, Jallouli Y, Kroubi M, Yuan X, Feng W, Kang C. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood \u2013 brain barrier. Int Jpurnal Pharm. 2009;379:285\u201392.","journal-title":"Int Jpurnal Pharm"},{"key":"764_CR90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0007373","volume":"13","author":"P Macgregor","year":"2019","unstructured":"Macgregor P, Gonzalez-Munoz AL, Jobe F, Taylor MC, Rust S, Sandercock AM, et al. A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. PLoS Negl Trop Dis. 2019;13:1\u201320.","journal-title":"PLoS Negl Trop Dis"},{"key":"764_CR91","doi-asserted-by":"crossref","unstructured":"Tachibana H, Yoshihara E, Kaneda Y, Nakae T. In vitro lysis of the bloodstream forms of Trypanosoma brucei gambiense by stearylamine-bearing liposomes 1988;32:966\u201370.","DOI":"10.1128\/AAC.32.7.966"},{"key":"764_CR92","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2736(86)90068-4","volume":"854","author":"E Yoshihara","year":"1986","unstructured":"Yoshihara E, Nakac T. Cytolytic activity of liposomes containing stearylamine. Biochim Biophys Acta. 1986;854:93\u2013101.","journal-title":"Biochim Biophys Acta"},{"key":"764_CR93","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1211\/002235703765344559","volume":"55","author":"SG Antimisiaris","year":"2003","unstructured":"Antimisiaris SG, Ioannou PV, Loiseau PM. In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB \/ c mice. J Pharm Pharmacol. 2003;55:647\u201352.","journal-title":"J Pharm Pharmacol"},{"key":"764_CR94","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejpb.2008.05.012","volume":"70","author":"S Zirar","year":"2008","unstructured":"Zirar S, Ben AA, Muchow M, Gibaud S. Comparison of nanosuspensions and hydroxypropyl- b -cyclodextrin complex of melarsoprol : Pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm. 2008;70:649\u201356.","journal-title":"Eur J Pharm Biopharm"},{"key":"764_CR95","doi-asserted-by":"crossref","unstructured":"Arias JL, Unciti-broceta JD, Maceira J, Hern\u00e1ndez-quero J, Magez S, Soriano M, et al. Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis. J Control Release. Elsevier B.V.; 2015;197:190\u20138.","DOI":"10.1016\/j.jconrel.2014.11.002"},{"key":"764_CR96","first-page":"1","volume":"505102","author":"M Kroubi","year":"2010","unstructured":"Kroubi M, Daulouede S, Karembe H. Development of a nanoparticulate formulation of diminazene to treat African trypanosomiasis. Nanotechnology. 2010;505102:1\u20138.","journal-title":"Nanotechnology."},{"key":"764_CR97","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exppara.2016.04.015","volume":"166","author":"MD Baldissera","year":"2016","unstructured":"Baldissera MD, Grando TH, Souza CF, Cossetin LF, Ana PT, Dalla DF, et al. Experimental parasitology nerolidol nanospheres increases its trypanocidal efficacy against Trypanosoma evansi : new approach against diminazene aceturate resistance and toxicity. Exp Parasitol. 2016;166:144\u20139.","journal-title":"Exp Parasitol"},{"key":"764_CR98","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2217\/nnm.13.148","volume":"9","author":"A Manuja","year":"2014","unstructured":"Manuja A. Quinapyramine sulfate-loaded sodium alginate nanoparticles show enhanced trypanocidal activity. Nanomedicine. 2014;9:1625\u201334.","journal-title":"Nanomedicine."},{"key":"764_CR99","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nanoso.2018.05.001","volume":"16","author":"A Manuja","year":"2018","unstructured":"Manuja A. Nano-structures & nano-objects chitosan quinapyramine sulfate nanoparticles exhibit increased trypanocidal activity in mice. Nano-Structures & Nano-Objects. 2018;16:193\u20139.","journal-title":"Nano-Structures & Nano-Objects"},{"key":"764_CR100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ijbiomac.2016.07.084","volume":"92","author":"S Singh","year":"2016","unstructured":"Singh S. Synthesis and evaluation of isometamidium-alginate nanoparticles on equine mononuclear and red blood cells. Int J Biol Macromol. 2016;92:788\u201394.","journal-title":"Int J Biol Macromol"},{"key":"764_CR101","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.2042-7158.1998.tb03301.x","volume":"50","author":"G Gonzalez-martin","year":"1998","unstructured":"Gonzalez-martin G, Mkrino I, Rodriguez-cabezas MN. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. J Pharm Pharmacol. 1998;50:29\u201335.","journal-title":"J Pharm Pharmacol"},{"key":"764_CR102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0939-6411(99)00076-4","volume":"49","author":"G Gonza","year":"2000","unstructured":"Gonza G. Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier : preparation and trypanocidal activity. Eur J Pharm Biopharm. 2000;49:137\u201342.","journal-title":"Eur J Pharm Biopharm"},{"key":"764_CR103","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/47.1.101","volume":"47","author":"J Molina","year":"2001","unstructured":"Molina J, Urbina J, Gref R, Brener Z, Maciel J, J\u00fanior R. Incorporated into \u2018 stealth \u2019 polyethyleneglycol \u2013 polylactide nanospheres. J Antimicrob Chemother. 2001;47:101\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"764_CR104","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1017\/S0031182018000197","volume":"145","author":"LD Tessarolo","year":"2018","unstructured":"Tessarolo LD, R\u00f3seo R, Pessoa P, De Menezes B, Mello CP, Lima DB, et al. Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to Trypanosoma cruzi. Parasitology. 2018;145:1191\u20138.","journal-title":"Parasitology."},{"key":"764_CR105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4269\/ajtmh.15-0889","volume":"95","author":"ML Scalise","year":"2016","unstructured":"Scalise ML, Arr\u00faa EC, Rial MS, Esteva MI, Salomon CJ, Fichera LE. Promising efficacy of benznidazole nanoparticles in acute Trypanosoma cruzi murine model : in-vitro and in-vivo studies. Am Soc Trop Med Hyg. 2016;95:388\u201393.","journal-title":"Am Soc Trop Med Hyg"},{"key":"764_CR106","unstructured":"Esteva I, Scalise L, Arru EC, Rial MS, Salomon J, Fichera LE. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease. PLoS Negl Trop Dis. 2017:1\u201316."},{"key":"764_CR107","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jconrel.2004.12.012","volume":"103","author":"MJ Morilla","year":"2005","unstructured":"Morilla MJ, Montanari J, Frank F, Malchiodi E, Corral R, Patricia Petray ELR. Etanidazole in pH-sensitive liposomes: design , characterization and in vitro \/ in vivo anti-Trypanosoma cruzi activity. J Control Release. 2005;103:599\u2013607.","journal-title":"J Control Release"},{"key":"764_CR108","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.exppara.2016.09.018","volume":"170","author":"MD Baldissera","year":"2016","unstructured":"Baldissera MD, Grando TH, De Souza CF, Cossetin LF, Silva APT, Giongo JL, et al. A nanotechnology based new approach for Trypanosoma evansi chemotherapy: in vitro and vivo trypanocidal effect of (-)-\u03b1-bisabolol. Exp Parasitol. 2016;170:156\u201360.","journal-title":"Exp Parasitol"},{"key":"764_CR109","doi-asserted-by":"crossref","unstructured":"Branquinho RT, Roy J, Farah C, Garcia GM, Aimond F, Le Guennec J, et al. Biodegradable polymeric nanocapsules prevent cardiotoxicity of anti- trypanosomal lychnopholide. Sci Reports-Nature. 2017:1\u201313.","DOI":"10.1038\/srep44998"},{"key":"764_CR110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1017\/S0031182014001292","volume":"142","author":"LT Gressler","year":"2015","unstructured":"Gressler LT, Oliveira CB, Coradini K, Rosa LD. Trypanocidal activity of free and nanoencapsulated curcumin on Trypanosoma evansi. Parasitology. 2015;142:439\u201348.","journal-title":"Parasitology."},{"key":"764_CR111","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.micpath.2017.02.005","volume":"105","author":"CF Souza","year":"2017","unstructured":"Souza CF, Baldissera MD, Cossetin LF, Dalla DF, Monteiro SG. Microbial pathogenesis achyrocline satureioides essential oil loaded in nanocapsules ameliorate the antioxidant \/ oxidant status in heart of rats infected with Trypanosoma evansi. Microb Pathog Elsevier Ltd. 2017;105:30\u20136.","journal-title":"Microb Pathog Elsevier Ltd"},{"key":"764_CR112","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mimet.2012.07.013","volume":"91","author":"I Eger","year":"2012","unstructured":"Eger I, Jos\u00e9 M. Endocytosis in Trypanosoma cruzi ( Euglenozoa : Kinetoplastea ) epimastigotes : visualization of ingested transferrin \u2013 gold nanoparticle complexes by confocal laser microscopy. J Microbiol Methods. 2012;91:101\u20135.","journal-title":"J Microbiol Methods"},{"key":"764_CR113","doi-asserted-by":"crossref","first-page":"e2847","DOI":"10.1371\/journal.pntd.0002847","volume":"8","author":"ZA Carneiro","year":"2014","unstructured":"Carneiro ZA, Maia PIS, Sesti-costa R, Lopes CD, Pereira TA, Silva S, et al. In vitro and in vivo trypanocidal activity of H 2 bdtc-loaded solid lipid nanoparticles. PLoS Negl Trop Dis. 2014;8:e2847.","journal-title":"PLoS Negl Trop Dis"},{"key":"764_CR114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.exppara.2014.03.007","volume":"141","author":"MD Baldissera","year":"2014","unstructured":"Baldissera MD, Da AS, Oliveira CB, Santos RCV, Vaucher RA, Raffin RP, et al. Experimental parasitology trypanocidal action of tea tree oil ( Melaleuca alternifolia ) against Trypanosoma evansi in vitro and in vivo used mice as experimental model. Exp Parasitol. 2014;141:21\u20137.","journal-title":"Exp Parasitol"},{"key":"764_CR115","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.msec.2017.03.266","volume":"77","author":"B Riul","year":"2017","unstructured":"Riul B, Campos PM, Baruffi MD, Marchetti JM. Poly-epsilon-caprolactone nanoparticles enhance ursolic acid in vivo efficacy against Trypanosoma cruzi infection. Mater Sci Eng C. 2017;77:1196\u2013203.","journal-title":"Mater Sci Eng C"},{"key":"764_CR116","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.2217\/nnm.15.167","volume":"10","author":"JA Garcia-salcedo","year":"2015","unstructured":"Garcia-salcedo JA, Unciti-broceta JD. Could specific cell targeting overcome resistance associated with current treatments for African trypanosomiasis ? Nanomedicine. 2015;10:3515\u20137.","journal-title":"Nanomedicine."},{"key":"764_CR117","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nm1395","volume":"12","author":"K Conrath","year":"2006","unstructured":"Conrath K, Vanhollebeke B, Pays E, Baral TN, Magez S, Muyldermans S, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. 2006;12:580\u20134.","journal-title":"Nat Med"},{"key":"764_CR118","first-page":"1","volume":"6","author":"JC Munday","year":"2015","unstructured":"Munday JC, Settimo L, Harry P, Koning D. Transport proteins determine drug sensitivity and resistance in a protozoan parasite. Trypanosoma brucei. 2015;6:1\u201311.","journal-title":"Trypanosoma brucei"},{"key":"764_CR119","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkt442","volume":"69","author":"JC Munday","year":"2014","unstructured":"Munday JC, Eze AA, Baker N, Glover L, Clucas C, Andre DA, et al. Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. J Antimicrob Chemother. 2014;69:651\u201363.","journal-title":"J Antimicrob Chemother"},{"key":"764_CR120","doi-asserted-by":"crossref","unstructured":"Molina I, Salvador F, Serre N, Almirante B. Toxic profile of benznidazole in patients with chronic Chagas disease: risk factors and comparison of the product from two 2015;59:6125\u201331.","DOI":"10.1128\/AAC.04660-14"},{"key":"764_CR121","doi-asserted-by":"crossref","unstructured":"Khalil NM, Mattos AC De, Cristina T, Moreira M, Brustolin D, Mainardes RM. Nanotechnological trategies for the treatment of neglected diseases 2013;7316\u201329.","DOI":"10.2174\/138161281941131219135458"},{"key":"764_CR122","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijpharm.2004.03.025","volume":"278","author":"MJ Morilla","year":"2004","unstructured":"Morilla MJ, Montanari JA, Prieto MJ, Lopez MO, Petray PB, Romero EL. Intravenous liposomal benznidazole as trypanocidal agent : increasing drug delivery to liver is not enough. Int J Pharm. 2004;278:311\u20138.","journal-title":"Int J Pharm"},{"key":"764_CR123","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-5173(02)00453-2","volume":"249","author":"MJ Morilla","year":"2002","unstructured":"Morilla MJ, Bena P, Lopez MO, Bakas L, Romero EL. Development and in vitro characterisation of a benznidazole liposomal formulation. Int J Pharm. 2002;249:89\u201399.","journal-title":"Int J Pharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-020-00764-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00764-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:45:37Z","timestamp":1620438337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-020-00764-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1007\/s13346-020-00764-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"8 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}